C5 inhibitors are not C5a inhibitors

被引：0
|
作者：
Lim, Endry H. T. [1 ,2 ,3 ]
Vlaar, Alexander P. J. [1 ]
de Bruin, Sanne [1 ]
Brouwer, Matthijs C. [2 ]
van de Beek, Diederik [2 ]
机构：
[1] Amsterdam UMC locat Univ Amsterdam, Dept Intens Care Med, Amsterdam, Netherlands
[2] Amsterdam UMC locat Univ Amsterdam, Dept Neurol, Amsterdam, Netherlands
[3] Amsterdam UMC, Dept Intens Care Med, Locat AMC, Room C3-421,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2023年 / 21卷 / 06期
关键词：
D O I：
10.1080/14787210.2023.2197211
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：685 / 686
页数：2
相关论文
共 50 条
  • [31] POTENTIAL COMPLEMENT INHIBITORS BLOCKING RELEASE OF C5A BASED ON A NATURAL PRODUCT MODEL
    SINDELAR, RD
    BRADBURY, BJ
    KAUFMAN, TS
    LEEL, C
    MARSH, HC
    SCESNEY, S
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1990, 200 : 178 - MEDI
  • [32] C5A AND ANTIGEN-INDUCED TRACHEAL CONTRACTION - EFFECT OF CYCLOOXYGENASE INHIBITORS AND AN ANTIHISTAMINE
    REGAL, JF
    PICKERING, RJ
    [J]. FEDERATION PROCEEDINGS, 1981, 40 (03) : 1115 - 1115
  • [33] SUBSTITUTED 4,6-DIAMINOQUINOLINES AS INHIBITORS OF C5A RECEPTOR-BINDING
    LANZA, TJ
    DURETTE, PL
    ROLLINS, T
    SICILIANO, S
    CIANCIARULO, DN
    KOBAYASHI, SV
    CALDWELL, CG
    SPRINGER, MS
    HAGMANN, WK
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (02) : 252 - 258
  • [34] Inactivation of C5a anaphylatoxin by a peptide that is complementary to a region of C5a
    Fujita, E
    Farkas, M
    Campbell, W
    Baranyi, L
    Okada, H
    Okada, N
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (10): : 6382 - 6387
  • [35] Augmenting role of complement C5/C5a in T cell-mediated contact sensitivity (CS).
    Tsuji, RF
    Askenase, PW
    [J]. FASEB JOURNAL, 1996, 10 (06): : 1896 - 1896
  • [36] Complement Proteins C5/C5a, Cathepsin D and Prolactin in Chondrocytes: A Possible Crosstalk in the Pathogenesis of Osteoarthritis
    Silawal, Sandeep
    Wagner, Miriam
    Roth, Dominik
    Bertsch, Thomas
    Schwarz, Silke
    Willauschus, Maximilian
    Gesslein, Markus
    Triebel, Jakob
    Schulze-Tanzil, Gundula
    [J]. CELLS, 2022, 11 (07)
  • [37] CHEMOTACTIC FACTOR FOR TUMOR-CELLS DERIVED FROM THE C5A FRAGMENT OF COMPLEMENT COMPONENT C5
    ORR, W
    PHAN, SH
    VARANI, J
    WARD, PA
    KREUTZER, DL
    WEBSTER, RO
    HENSON, PM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (04) : 1986 - 1989
  • [38] INHIBITION OF C5 CONVERTASE BY EPSILON AMINOCAPROIC ACID (EACA) - LIMITING FACTOR IN GENERATION OF C5A ANAPHYLATOXIN (AT)
    VALLOTA, EH
    [J]. FEDERATION PROCEEDINGS, 1977, 36 (03) : 1245 - 1245
  • [39] Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors
    Obara, Naoshi
    Usuki, Kensuke
    Hayashi, Takeshi
    Fujii, Masato
    Ikezoe, Takayuki
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (03) : 255 - 264
  • [40] The clinical potential of Affibody-based inhibitors of C5 for therapeutic complement disruption
    Berglund, Magnus M.
    Stromberg, Patrik
    [J]. EXPERT REVIEW OF PROTEOMICS, 2016, 13 (03) : 241 - 243
12345